Stemline Therapeutics
Focus: Stemline Therapeutics is a 5,000+ employee oncology-focused biotech company headquartered in New York, specializing in cancer stem cell therapies and cell-based treatments. The company is entirely revenue-dependent on its lead product ORSERDU (elacestrant), an estrogen receptor antagonist for breast cancer.
Profile data last refreshed 15h ago · AI intelligence enriched 3w ago
Employees
5000+
Open Jobs
0
About Stemline Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Stemline Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Stemline Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$128M Part DStable
Peak11.2yr
Sole revenue driver representing 100% of company revenue; estrogen receptor antagonist with patent protection through 2038.
Help build intelligence for Stemline Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.